Marker Therapeutics Files 8-K on Director Changes and Compensation
Ticker: MRKR · Form: 8-K · Filed: Nov 5, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
TL;DR
Marker Therapeutics filed an 8-K on 10/31/25 covering director changes and exec comp.
AI Summary
On October 31, 2025, Marker Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes information on other events and financial statements, with the company's fiscal year ending on December 31st.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is routine and primarily reports on corporate governance and compensation matters, not significant financial distress or operational changes.
Key Numbers
- 20251031 — Report Date (Date of earliest event reported)
- 1231 — Fiscal Year End (Company's fiscal year end)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- TAPIMMUNE INC. (company) — Former Company Name
- GENEMAX CORP (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific changes were made to the board of directors?
The filing indicates 'Departure of Directors or Certain Officers; Election of Directors' as an item of information, suggesting changes occurred, but the specific details of who departed or was elected are not provided in this excerpt.
What are the key aspects of the compensatory arrangements mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item of information, indicating that details regarding executive compensation are included, but the specifics are not detailed in this excerpt.
What is the significance of the 'Other Events' section?
The 'Other Events' section is a catch-all for significant events that do not fit into other standard 8-K categories, and its content would need to be reviewed in the full filing.
When was Marker Therapeutics, Inc. previously known by other names?
Marker Therapeutics, Inc. was formerly known as TAPIMMUNE INC. (name change on 20170629 and 20070628) and GENEMAX CORP (name change on 20020718).
What is the company's primary industry classification?
Marker Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 966 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2025-11-05 07:36:59
Key Financial Figures
- $0.001 — h registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
Filing Documents
- tm2530129d1_8k.htm (8-K) — 30KB
- tm2530129d1_ex99-1.htm (EX-99.1) — 12KB
- tm2530129d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-25-106669.txt ( ) — 217KB
- mrkr-20251031.xsd (EX-101.SCH) — 3KB
- mrkr-20251031_lab.xml (EX-101.LAB) — 33KB
- mrkr-20251031_pre.xml (EX-101.PRE) — 22KB
- tm2530129d1_8k_htm.xml (XML) — 4KB
01. Other Information
Item 8.01. Other Information On November 5, 2025, the Company issued a press release announcing the appointment of Ms. Corzo to its Board. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated November 5, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: November 5, 2025 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer